Media headlines about Biogen (NASDAQ:BIIB) have trended somewhat positive on Friday, according to InfoTrie. The research firm ranks the sentiment of media coverage by reviewing more than 6,000 blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biogen earned a media sentiment score of 1.08 on their scale. InfoTrie also assigned news headlines about the biotechnology company an news buzz score of 10 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company’s share price in the near future.
These are some of the media headlines that may have impacted Biogen’s analysis:
- Let’s Talk About Biogen’s Stunning Alzheimer’s Drug Reversal: Brainstorm Health – Fortune (fortune.com)
- Biogen Aducanumab Reversal Is Stunning, But Don’t Expect A Repeat For Other Alzheimer’s Drugs – Seeking Alpha (seekingalpha.com)
- Biogen, Amyloid, And Alzheimer’s Disease: Once More Down The Rabbit Hole – Seeking Alpha (seekingalpha.com)
- Listen: Every angle on Biogen’s shocking Alzheimer’s news – STAT (statnews.com)
- Bank of America Increases Biogen (NASDAQ:BIIB) Price Target to $235.00 (americanbankingnews.com)
BIIB opened at $285.68 on Friday. The stock has a market cap of $51.99 billion, a PE ratio of 10.90, a P/E/G ratio of 1.53 and a beta of 1.02. The company has a current ratio of 1.91, a quick ratio of 2.22 and a debt-to-equity ratio of 0.35. Biogen has a 1 year low of $215.77 and a 1 year high of $344.00. The stock’s 50 day simple moving average is $232.25 and its 200-day simple moving average is $231.64.
Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Tuesday, October 22nd. The biotechnology company reported $9.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.27 by $0.90. The business had revenue of $3.60 billion for the quarter, compared to analysts’ expectations of $3.53 billion. Biogen had a return on equity of 46.14% and a net margin of 37.91%. Biogen’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the business posted $7.40 earnings per share. Equities analysts forecast that Biogen will post 32.4 earnings per share for the current fiscal year.
A number of brokerages recently weighed in on BIIB. Morgan Stanley raised their price objective on Biogen from $212.00 to $262.00 and gave the company an “underweight” rating in a research note on Wednesday. Oppenheimer set a $280.00 price objective on Biogen and gave the company a “buy” rating in a research note on Tuesday, October 15th. Bank of America lifted their price target on Biogen from $200.00 to $235.00 and gave the stock an “underperform” rating in a research report on Wednesday. ValuEngine raised Biogen from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Finally, Stifel Nicolaus lifted their price target on Biogen from $236.00 to $296.00 and gave the stock a “hold” rating in a research report on Tuesday. Five investment analysts have rated the stock with a sell rating, nineteen have issued a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $288.33.
Biogen Company Profile
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.
See Also: What is meant by a buy rating?
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.